tation  Vaccine‐like immunity post‐mAb therapy  FcγRIIa, FcγRI, FcγRIIIa
Inhibition  Reduce B‐cell proliferation or innate cell activation by antibody complexes  Inhibition of ITAM cell activation (i.e. BCR) or activating‐